TABLE 2.

Patient and Tumor Characteristics and Outcomes (n = 21), Including Individual Patient Data on All Parameters Collected

								During-treatment SUV_max		SUV_max change from baseline (%)		CT
Patient no.	Sex	Age (y)	Tumor stage	Smoking history	No. of prior treatment regimens	Histology	Baseline SUV_max	1–2 wk	6 wk	1–2 wk	6 wk	6 wk	Best response	Time to progression (mo)	OS (mo)
1	F	69	IV	None	1	Adenocarcinoma	1.81	3.15	3.64	74	101	Stable disease	Stable disease	1.9	4.5
2	M	73	IV	Former	1	Adenocarcinoma	3.24	3.17	2.76	−2	−15	Stable disease	PR	3.6	7.5
3	M	79	IV	Former	1	Adenocarcinoma	5.93	5.57	4.12	−6	−31	PR	PR	9.0	14.1
4	F	65	IV	Former	2	SCC	1.75	1.98	1.28	13	−27	Stable disease	Stable disease	1.6	3.6
5	F	50	IV	None	2	Adenocarcinoma	4.70	ND	ND	NA	NA	PR	PR	5.1	11.4
6	F	54	IV	None	2	Adenocarcinoma	1.98	2.24	3.70	13	87	PD	PD	1.2	4.7
7	M	62	IV	Former	2	SCC	5.53	5.16	4.97	−7	−10	PR	PR	7.9	11.6
8	M	75	IV	Former	1	Adenocarcinoma	1.26	1.09	ND	−13	NA	PD	PD	0.4	0.9
9	F	62	IV	None	2	Adenocarcinoma	2.92	ND	ND	NA	NA	Stable disease	Stable disease	3.3	8.1
10	F	45	IV	None	2	SCC	2.37	2.98	3.13	26	33	Stable disease	Stable disease	2.2	12.3
11	F	46	IV	None	3	Adenocarcinoma	4.61	3.57	3.41	−23	−26	PD	PD	1.6	4.2
12	F	73	IV	None	1	SCC	2.60	ND	ND	NA	NA	Stable disease	Stable disease	2.8	6.5
13	M	59	IV	Former	2	SCC	1.98	1.02	1.21	−48	−39	PD	PD	1.0	2.6
14	F	39	IV	None	2	Adenocarcinoma	3.32	2.96	1.86	−11	−44	Stable disease	PR	3.9	8.5
15	F	64	IV	None	2	Adenocarcinoma	4.76	3.31	2.45	−30	−49	PR	PR	5.5	11.8+
16	M	47	IIIB	Former	2	SCC	3.60	1.90	2.03	−47	−44	PR	PR	4.4	8.8
17	F	72	IV	None	1	Adenocarcinoma	2.33	2.46	3.47	6	49	Stable disease	Stable disease	2.4	4.9
18	M	61	IV	Former	2	Adenocarcinoma	4.95	4.62	3.49	−7	−29	PR	PR	6.7	12.1+
19	F	63	IV	Former	2	Adenocarcinoma	1.63	1.79	ND	10	NA	PD	PD	0.8	1.4
20	M	55	IV	Current	2	Adenocarcinoma	2.54	2.49	3.24	−2	28	Stable disease	Stable disease	2.5	6.7
21	F	52	IV	None	2	Adenocarcinoma	3.58	2.96	2.79	−17	−22	Stable disease	PR	4.2	12.4+

SCC = squamous cell carcinoma; PD = progressive disease; PR = partial response; ND = not done; NA = not applicable; + = patients alive at last follow-up.